EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Structural Simplification from Tricyclic to Bicyclic Scaffolds: A Long-Term Investigation in the Field of Adenosine Receptor Antagonists

Costanza Ceni, Sara Calenda iD, Giulia Vagnoni, Daniela Catarzi iD, Flavia Varano, Vittoria Colotta iD

Cells · 2025

DOI: 10.3390/cells14181480 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, 2025. Verfasst von Costanza Ceni und 5 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Neuroscienze, Psicologia, Area del Farmaco e Salute del Bambino, Sezione di Farmaceutica e Nutraceutica, Università degli Studi di Fi…. Hauptthemen laut MEDLINE: Quinoxalines, Triazines, Pyrazoles, Adenosine A2 Receptor Antagonists. Die Arbeit nennt 213 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Florence, NEXT-GENERATION-EU (NGEU)-National Recovery and Resilience Plan (NRRP), Investment 1.5-Ministry of University and Research (MUR) Call n° 3277.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adenosine receptor (AR) antagonists have attracted considerable interest due to their therapeutic potential in a wide range of pathological conditions, including neurological, cardiovascular, and inflammatory disorders. Although a large number of AR antagonists have been developed worldwide, the interest in new derivatives remains high, and achieving subtype selectivity continue to be a major challenge. This review summarizes our research on adenosine receptor antagonists, highlighting the discovery of potent and selective compounds for the diverse AR subtypes across various chemical classes. Specifically, the paper focuses on the study of the triazolo[4,3-a]quinoxalin-1-one (TQX) and pyrazolo[3,4-c]quinoline (PQ) series, along with their simplified analogues, which have yielded highly potent and selective AR antagonists. An overview of the structure–activity relationship (SAR) studies and molecular docking investigations is provided, emphasizing the structural requirements for A2A and A3 receptor–ligand interaction. In addition, we present pharmacological studies of selected AR antagonists, in various in vitro and in vivo models of pain, depression, neuroinflammation-related diseases, and cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

QuinoxalinesTriazinesPyrazolesAdenosine A2 Receptor AntagonistsAdenosine A3 Receptor AntagonistsStructure-Activity RelationshipHumansLigandsPainDepressionNeuroinflammatory DiseasesNeoplasmsAnimals

Stichwörter der Autor:innen

adenosine receptor antagonistsadenosine receptorsantinociceptivecancerdepressionneuroinflammationneuroprotection

Substanzen

QuinoxalinesTriazinesPyrazolesAdenosine A2 Receptor AntagonistsAdenosine A3 Receptor AntagonistsLigands

Autor:innen und Institutionen

  • Dipartimento di Neuroscienze, Psicologia, Area del Farmaco e Salute del Bambino, Sezione di Farmaceutica e Nutraceutica, Università degli Studi di Firenze, Via Ugo Schiff, 6, 50019 Sesto Fiorentino, Italy.

ORCID-Profile: Sara Calenda, Daniela Catarzi, Vittoria Colotta

Förderung

  • University of Florence
  • NEXT-GENERATION-EU (NGEU)-National Recovery and Resilience Plan (NRRP)
  • Investment 1.5-Ministry of University and Research (MUR) Call n° 3277

Zitieren

APA

Ceni, C., Calenda, S., Vagnoni, G., Catarzi, D., Varano, F., & Colotta, V. (2025). Structural Simplification from Tricyclic to Bicyclic Scaffolds: A Long-Term Investigation in the Field of Adenosine Receptor Antagonists. Cells. https://doi.org/10.3390/cells14181480

Vancouver

Ceni C, Calenda S, Vagnoni G, Catarzi D, Varano F, Colotta V. Structural Simplification from Tricyclic to Bicyclic Scaffolds: A Long-Term Investigation in the Field of Adenosine Receptor Antagonists. Cells. 2025. doi:10.3390/cells14181480

BibTeX
@article{Ceni2025,
  author = {Ceni, Costanza and Calenda, Sara and Vagnoni, Giulia and Catarzi, Daniela and Varano, Flavia and Colotta, Vittoria},
  title = {Structural Simplification from Tricyclic to Bicyclic Scaffolds: A Long-Term Investigation in the Field of Adenosine Receptor Antagonists},
  journal = {Cells},
  year = {2025},
  doi = {10.3390/cells14181480}
}
Kostenlos starten →